1 / 44

The Leukemias

The Leukemias. Sherron R. Helms, M.D. March 24, 2005. Leukemias. Proliferation of abnormal clone of hematopoietic cells Poor response to normal regulatory signals Diminished capacity for differentiation Ability to expand at expense of normal cells Ability to suppress growth of normal cells.

slone
Télécharger la présentation

The Leukemias

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Leukemias • Sherron R. Helms, M.D. • March 24, 2005

  2. Leukemias • Proliferation of abnormal clone of hematopoietic cells • Poor response to normal regulatory signals • Diminished capacity for differentiation • Ability to expand at expense of normal cells • Ability to suppress growth of normal cells

  3. Leukemias- Etiology • Generally unknown • Host susceptibility- DNA repair mechanisms, Down syndrome • Chromosomal damage- physical (XRT) or chemical (alkylating agents, benzene) • Viral- EBV in Burkitt, HTLV-I in T cell ALL

  4. Leukemias- Diagnosis • Generally requires bone marrow biopsy and aspirates with flow cytometry and cytogenetics • CLL can be reliably diagnosed by flow cytometry on peripheral blood • There must be > 20% blasts in marrow for diagnosis of acute leukemia

  5. Leukemias- Classification • Acute vs Chronic • Based on natural history of the untreated disease • Myeloid vs Lymphoid • Based on the primary cell line involved

  6. Leukemias • Lymphoid • CLL • ALL • Myeloid • CML • AML

  7. Chronic Lymphocytic Leukemia

  8. CLL • Relatively indolent clonal lymphoid disease • Primarily B cell • Includes Hairy Cell Leukemia • Most common leukemia in adults • Median age at diagnosis: 62 y • Etiology unknown • Morphology: Normal B cells

  9. CLL- Molecular Biology • Normal appearance, abnormal function • CD 5 expression • Defective apoptosis • Overexpression of bcl-2 gene

  10. CLL- Clinical Presentation • Asymptomatic • Lymphocytosis noted on routine CBC • Lymphadenopathy and/or splenomegaly in ~50% at diagnosis • Staph, Strep, Herpes infections common • Autoimmune hemolytic anemia in 10% • ITP in 2%

  11. CLL- Immune dysfunction • CLL B cells produce reduced levels of immunoglobulin in response to antigenic stimuli • Quantitative and qualitative abnormalities in B, T, NK cells • Impaired complement activation

  12. CLL- Staging • LOW RISK • Lymphocytosis only • Average survival >10 yrs • INTERMEDIATE RISK • + Adenopathy and/or splenomegaly • Average survival 7 yrs • HIGH RISK • + Anemia and/or thrombocytopenia • Average survival 1.5 yrs

  13. CLL- Clinical course • Generally, indolent with gradual increase in lymphocytosis, adenopathy, splenomegaly. May be years before Rx required • Richter syndrome- ~5% transform to aggressive large cell lymphoma/leukemia • Develop fever, weight loss, worsening anemia & thrombocytopenia, rising lymphocyte count • Short survival, poor response to therapy

  14. CLL- Treatment • No survival advantage to therapy at time of diagnosis in low risk patients • Indications for therapy: • B symptoms • AIHA, ITP (steroids) • Massive hepatosplenomegaly • Bulky adenopathy • Recurrent infections

  15. CLL- Treatment Options-I • Chlorambucil- Oral alkylator, ~50% RR, rare complete response • Fludarabine- IV purine analog, 70% RR, 30% CR, prolonged T cell suppression • IVIG: Only in pts with repeated bacterial infections

  16. CLL- Treatment Options-II • Monoclonal Antibodies • Rituximab- antiCD20; when combined with chemo, 95% RR, 68% CR • Alemtuzumab- antiCD52- effective in clearing blood and marrow; less effective on nodes. Prolonged, severe T cell suppression • Bone Marrow Transplantation- autologous and allogeneic under study for healthy pts under 70yo

  17. Hairy Cell Leukemia • Male predominance • Cytopenias, splenomegaly • Therapy: Cladribine- nucleoside analog • Single course of therapy • 90% response rate • Responses very durable • Resistant disease- BL-22: MoAb antiCD22 + pseudomonas exotoxin induces apoptosis- 75% RR in clinical trials

  18. Acute lymphocytic leukemia

  19. Acute lymphoblastic leukemia • Malignant disease of early B and T cells • Aberrant differentiation and proliferation • Cells accumulate in marrow and suppress normal hematopoiesis • In addition to marrow and peripheral blood, involves nodes, liver, spleen, CNS, and skin

  20. A.L.L. • 20% of adult leukemia • Most common malignant disease in childhood • Symptoms: fatigue, fevers, bone pain, infection, bleeding, adenopathy • CNS involvement in 5-10% • Blasts in peripheral blood in 90% • Leukostasis uncommon even with WBC 100,000

  21. A.L.L. Treatment • Induction, consolidation, maintenance • Use multiple chemotherapy agents to prevent resistance (vincristine, prednisone, daunorubicin, asparaginase) • Use prophylactic Rx of CNS (intrathecal methotrexate and AraC) • Postremission chemo to eliminate minimal residual disease • Adults: 65-90% remission; 20-30% cure • Allogeneic transplants in high risk pts

  22. Acute Myelogenous Leukemia

  23. A.M.L. • Most common acute leukemia in adults • Median age at diagnosis: 60 yrs • The most common type of leukemia induced by alkylating agents (nitrogen mustard [7y]) or epipodophyllins (VP16, 1-2 y)

  24. AML • Auer rods: accumulation of lysosomal granules in cytoplasm, seen in ~10% • Diagnosis by flow cytometry, cytogenetics on marrow • FAB classification has 8 subtypes (M0- M7); WHO classification has 19

  25. AML- Clinical Features • Presenting symptoms: fatigue, bruising, infection • Acute promyelocytic subtype presents with bleeding, sometimes frank DIC • Acute myelomonocytic subtype often has gum and/or skin involvement • Leukostasis (pulm and CNS) common when blast count >50,000

  26. A.M.L.- Therapy • Remission induction with cytarabine and daunorubicin • all-trans retinoic acid (ATRA) is added in acute promyelocytic leukemia (APL) • Postremission: consolidation chemo using high dose cytarabine for 2 cycles • 40% cure rate in young and middle aged adults • Maintenance therapy only in APL (ATRA) • Allogeneic transplant in high risk pts <70y who have match and are in CR

  27. AML in Elderly • Poorer outcome, ~10% long term survivors • Less able to withstand intensive chemotherapy and complication of prolonged marrow suppression • Less marrow regenerative capacity • More often have poor-prognosis subtypes of leukemia • More often have MDS evolving into AML, multiple mutations and drug resistant

  28. Acute Promyelocytic Leukemia (APL) • M3 subtype of AML • Promyelocytes contain granules with procoagulant and fibrinolytic activity • t(15;17) juxtaposes the RARa gene on 17 with the PML gene on 15 • The resulting PML/RARa represses transcription of the RAR needed for differentiation/apoptosis • High doses of ATRA cause release of the corepressor

  29. A.P.L. • Retinoic acid + standard chemotherapy with daunorubicin and cytosine arabinoside (AraC) • 95% remission rate, 70% cure rate • Arsenic trioxide active in relapsed disease (causes histone acetylation, differentiation, & apoptosis)

  30. Chronic Myelogenous Leukemia

  31. Chronic Myelogenous Leukemia • A myeloproliferative disorder (CML, P. Vera, E.T.) • Clonal disorder of pluripotential stem cell • Median age 45-55 yrs • Philadelphia chromosome [t(9;22)] in 95%

  32. CML • Expansion of myeloid cells at various stages of maturation • Three clinical phases: chronic, accelerated, and blast crisis • Patients proceed through these phases over ~4yrs if untreated • Symptoms: fatigue, night sweats, sx related to splenomegaly • High WBC, increased basophils, high platelet count

  33. Ph Chromosome • BCR-ABL –protein product of the translocation • Transfection of BCR-ABL in mice causes CML • Inhibition of BCR-ABL in patients reverses CML • Acquired disorder • Cause of mutation unknown- radiation in some

  34. Ph Chromosome- BCR-ABL • Tyrosine kinase activity • Leads to increased transcription of genes that control cell proliferation • Inhibits expression of cell adhesion molecules • Suppresses apoptosis

  35. CML- Treatment • The BCR-ABL proteins must be phosphorylated to have tyrosine kinase activity • Imatinib (Gleevec) blocks phosphorylation • Oral agent, well tolerated • 87% RR, 76% complete cytogenetic response • Allogeneic stem cell transplant cures 75% of pts under age 70

More Related